Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
These transactions were part of regular financial management by the manager and are publicly disclosed to provide transparency to shareholders and potential investors. For in-depth information on TVTX’s value and a full review, including 10 valuable ProTips and detailed financial metrics, visit InvestingPro. For in-depth information on TVTX’s value and a full review, including 10 valuable ProTips and detailed financial metrics, visit InvestingPro.
These transactions were part of regular financial management by the manager and are publicly disclosed to provide transparency to shareholders and potential investors. For in-depth information on TVTX’s value and a full review, including 10 valuable ProTips and detailed financial metrics, visit InvestingPro.
These transactions were part of regular financial management by the manager and are publicly disclosed to provide transparency to shareholders and potential investors.
In other recent news, biopharmaceutical company Travere Therapeutics has announced its plan to make a public offering of its common stock, managed by Jefferies and Leerink Partners. The firm has not disclosed specifics regarding the use of proceeds from the offering. In financial terms, Travere reported strong growth in Q3 2024, with sales of online products reaching $35.6 million, an increase of 30% from the previous quarter, mainly driven by the production of the drug business its FILSPAIR for IgA nephropathy. Summary (EPA:) revenue for the quarter rose to $62.9 million, marking a 69% increase from the same period in 2023. However, the company also reported a net loss of $ 54.8 million, resulting from a one-time profit from the sale of the product. last year. Despite the net loss, Travere maintains a strong cash position of $277.4 million. In addition, the company is advancing its sparsentan program for Focal Segmental Glomerulosclerosis, with promising study results and upcoming regulatory discussions. These latest developments reflect Travere’s continued commitment to its growth strategies.
This article was created with the support of AI and reviewed by the editor. For more details, see our T&C.
